As a result, small-molecule GS inhibitors (GSIs) were found to increase BCMA and decrease sBCMA levels simultaneously and augment CAR-T efficacy in MM pre-clinical models [49]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.